U.S. High Court To Hear Fosamax Preemption Case Jan. 7; Solicitor General Included
(December 3, 2018, 12:52 PM EST) -- WASHINGTON, D.C. — Arguments about whether the Food and Drug Administration rejected a stronger warning about leg fractures on the label of the osteoporosis drug Fosamax will be heard by the...
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login